ATOMIC phase III trial establishes standard-of-care for patients with stage 3 dMMR colon cancer

FDA issues reminder to sponsors: Disclose clinical trial results

FDA issued a stern reminder to medical product companies and researchers of the requirements to submit certain clinical trial results information to ClinicalTrials.gov.

Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

The START Center for Cancer Research, a community-based network of clinical trial sites specializing in early-phase oncology trials, announced the appointment of Salwan Al Mutar as director of Clinical Research at START Dallas-Fort Worth.

April 17, 2026

Vol.52 No.15

In Brief

Myriam Chalabi wins the grand prize for Innovators in Science Award by Takeda and Nature

Takeda and Nature announced the grand prize winner for the 2026 Innovators in Science Award—Myriam Chalabi, a medical oncologist at the Netherlands Cancer Institute.

April 17, 2026

Vol.52 No.15

Clinical Roundup

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

Patients with pancreatic cancer who received the experimental drug elraglusib, alongside standard chemotherapy, were twice as likely to be alive after one year of treatment, compared to those receiving chemotherapy alone, according to the results of a randomized phase II clinical trial conducted by researchers at Northwestern University. The drug also reduced the risk of death by 38%.

April 17, 2026

Vol.52 No.15

Clinical Roundup

First in-human trial primes immune system to accept donor livers, UPMC study finds

UPMC and University of Pittsburgh clinician-scientists have weaned and kept multiple liver transplantation patients off of all immunosuppressant drugs for more than three years through a first-in-human clinical trial of a unique “immune priming” therapy, according to the results of a small, early-stage trial.

April 17, 2026

Vol.52 No.15

Clinical Roundup

DYV800 topical therapy targets tumor acidity, preclinical study finds

A novel transdermal therapy designed to modulate tumor pH called DYV800 helped make tumors substantially less acidic, restore T-cell activity, slow tumor growth, and improve survival in preclinical studies, according to a study using animal models of bladder cancer conducted by Dyve Biosciences, in collaboration with Moffitt Cancer Center.

April 17, 2026

Vol.52 No.15

ATOMIC phase III trial establishes standard-of-care for patients with stage 3 dMMR colon cancer

YOU MAY BE INTERESTED IN

FDA issues reminder to sponsors: Disclose clinical trial results

Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

Myriam Chalabi wins the grand prize for Innovators in Science Award by Takeda and Nature

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

First in-human trial primes immune system to accept donor livers, UPMC study finds

DYV800 topical therapy targets tumor acidity, preclinical study finds

Renew today!

Subscriber content

Never miss an issue!

Login